OPRX
OptimizeRx Corp.
$9.42
Platform & Compounding FCF
85%
Two-stage FCF DCF
Strong
·
Conviction
Undervalued
Trading 89.3% below fair value
You pay
$9.42
Bear
$35.91
Fair
$88.05
Bull
$128.09
Bear
$35.91
+281.2%
18% stage 1 growth, 11% discount
Fair
$88.05
+834.7%
30% stage 1 growth, 11% discount
Bull
$128.09
+1259.7%
35% stage 1 growth, 11% discount
Adjust Assumptions
29.9%
11.0%
3.0%
Key Value Driver
FCF growth rate (30% base case)
Terminal Value % of EV
52%
Implied Market Multiple
10.4x
Market is pricing in (growth)
0.0%
vs 29.9% base
Analyst Consensus (External Reference)
Never blended into the bear/base/bull estimates above.
Average Target (15 analysts)
$10.25
Divergence from AlphaVal
759%
Summary
Using a two-stage FCF DCF with 30% growth decelerating over 15 years, discounted at 11%, the base-case intrinsic value is $88.05 per share.
Warnings
Stock-based employee pay equals 136% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.
Wall Street's average price target is $10.25 (from 15 analysts). Our estimate is 759% above the consensus -- consider that gap carefully.
Key Risks
- P/E alone misleads — earnings depressed by growth investment
- Cyclical or commodity businesses may be misclassified as platforms
- Terminal value dominance suggests sensitivity to long-run assumptions